Cetirizine hydrochloride is a second-generation histamine H1 antagonist that is effective in treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Cetirizine does not cause drowsiness or anticholinergic side effects opposed to conventional antihistamines. Cetirizine is available in various forms such as regular and chewable tablets, capsules, and solutions.

Market Dynamics

Increasing prevalence of allergic conditions in children and adult population is major factor driving growth of the cetirizine hydrochloride market. According to the National Health Interview Survey (NHIS), 2014, around 8.4% of children under the age of 18 suffered from hay fever, 10% from respiratory allergies, 5.4% from food allergies, and 11.6% from skin allergies in the U.S. Furthermore, allergic conjunctivitis imposes economic and social burden on the affected population, thereby increasing the adoption of efficient treatment to curb the increasing healthcare costs. According to the Department of Ophthalmology and Visual Sciences, University of Wisconsin, 2013, an estimated 6 million people are affected by bacterial conjunctivitis, annually in the U.S. The total expenditure in treatment of the disease was reported around US $377 million to US$ 857 million, annually.

Key features of the study

• This report provides in-depth analysis of the cetirizine hydrochloride market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by leading players
• It profiles leading players in the global cetirizine hydrochloride market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include, Johnson and Johnson, Mylan, Inc., Nicox S.A., Strides Shasun, Apotex, Inc., Teva UK Limited, Aurobindo Pharma Limited, Jubilant Life Sciences, Tris Pharma, Inc., and Cipla Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global cetirizine hydrochloride market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the cetirizine hydrochloride market

Market Segmentation

• By Dosage Form (Revenue, USD Bn, 2021-2033)
  • Tablet
  • Syrup
  • Solution
• By Age Group (Revenue, USD Bn, 2021-2033)
  • Adult
  • Pediatric
• By Application (Revenue, USD Bn, 2021-2033)
  • Allergic Rhinitis
  • Allergic Conjunctivitis
  • Eczema
  • Others
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Johnson and Johnson
  • Mylan, Inc.
  • Nicox S.A.
  • Strides Shasun
  • Apotex, Inc.
  • Teva UK Limited
  • Aurobindo Pharma Limited
  • Jubilant Life Sciences
  • Tris Pharma, Inc.
  • Cipla Ltd.